HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/1/2017)... ... March 01, 2017 , ... Breast Surgeon, Dr. Dennis Holmes of ... stage breast cancer and where it fits in the treatment paradigm at Susan G. ... .” The event brings together leading cancer and wellness experts to share the latest ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... increase colorectal cancer screening rates by supporting the 80% by 2018 initiative, led ... (CDC) and the National Colorectal Cancer Roundtable (an organization co-founded by ACS and ...
(Date:3/1/2017)... ... March 01, 2017 , ... “There is Comfort for the Soul”: a ... author in their all-too-brief time together, and the soul-healing comfort provided by God’s presence ... creation of published author, Jerie A. Tau, a dog-loving medical professional whose work takes ...
(Date:3/1/2017)... ... March 01, 2017 , ... “Letter of Love”: a tale of ... Teresa Hamilton, survivor of the Civil War in El Salvador, wife, mother, and co-founder ... of fifteen. I dedicated myself to serve in very poor communities, and I study ...
(Date:2/28/2017)... (PRWEB) , ... March 01, 2017 , ... ... the acquisition of SmarterMe, a personal assistant for sales powered by an intelligent ... enterprises to work smarter. , SmarterMe is built grounds up keeping individual users ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Research and Markets has announced the addition of the "Global ... their offering. ... This analysis is one of the most accurate studies performed using ... data derived from varied research sources to present unique and reliable ... during the next five years, including a deep dive analysis of ...
(Date:3/1/2017)... 1, 2017 Utilizing a cloud-based, HIPAA-compliant ... three-phase program that offers providers the ability to ... if desired – move toward a self-distribution model ... episode of care. "The reality is ... to decrease," says Amin Rahme , president ...
(Date:3/1/2017)... PRUSSIA, Pa. , March 1, 2017  Global ... it has completed the largest ever Chronic Inflammatory Demyelinating ... A nd T reatment with H ... designed to demonstrate the efficacy, safety and tolerability of ... Hizentra ® (Immune Globulin Subcutaneous [Human]), compared with ...
Breaking Medicine Technology:
Cached News: